Fludarabine, cyclophosphamide, and rituximab (FCR) plus GM-CSF as frontline treatment for patients with Chronic Lymphocytic Leukemia

FCR, the standard of care for frontline treatment of CLL patients, is associated with a high rate of neutropenia and infectious complications. GM-CSF reduces myelosuppression and can potentiate rituximab activity. We conducted a clinical trial combining GM-CSF with FCR for frontline treatment of 60...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Leuk Lymphoma
Main Authors: Strati, Paolo, Ferrajoli, Alessandra, Lerner, Susan, O’Brien, Susan, Wierda, William, Keating, Michael J, Faderl, Stefan
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4487862/
https://ncbi.nlm.nih.gov/pubmed/23808813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2013.819574
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares